| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Omnia Azmy Nabeh, Magdy Ishak Attallah, Nawal El-Sayed El-Gawhar. The pivotal relation between glucagon-like peptides, NFκB and inflammatory bowel disease. Clinical and experimental pharmacology & physiology. vol 47. issue 10. 2021-10-29. PMID:32511781. |
glp-1 plays a crucial role in lowering blood glucose and controlling body weight, through stimulating the islet ß cells of pancreas to secrete insulin, inhibiting gastric emptying, and reducing food ingestion. |
2021-10-29 |
2023-08-13 |
Not clear |
| Jens Juul Hols. Treatment of Type 2 Diabetes and Obesity on the Basis of the Incretin System: The 2021 Banting Medal for Scientific Achievement Award Lecture. Diabetes. vol 70. issue 11. 2021-10-29. PMID:34711671. |
after a brief discussion of their effect on insulin sensitivity, i describe their immediate actions in patients with type 2 diabetes and emphasize the actions of glp-1 on β-cell glucose sensitivity, followed by a discussion of their extrapancreatic actions, including effects on appetite and food intake in humans. |
2021-10-29 |
2023-08-13 |
Not clear |
| Chee W Chia, Josephine M Ega. Role and development of GLP-1 receptor agonists in the management of diabetes. Diabetes, metabolic syndrome and obesity : targets and therapy. vol 2. 2021-10-28. PMID:20148188. |
exogenous glp-1 administration at pharmacological doses results in many effects that are beneficial for treating type 2 diabetes, these include: (1) an increase in insulin secretion from beta cells; (2) a suppression of glucagon secretion from alpha cells in the presence of hyperglycemia but not hypoglycemia; (3) a delay in gastric emptying and gut motility which in turns delays absorption of ingested nutrients and dampens post-prandial glucose excursion; and (4) an increase in the duration of postprandial satiety therefore suppressing appetite and decreasing food intake which eventually leads to weight loss. |
2021-10-28 |
2023-08-12 |
human |
| Alejandra Perez-Montes DE Oca, Silvia Pellitero, Manel Puig-Doming. Obesity and GLP-1. Minerva endocrinology. vol 46. issue 2. 2021-10-28. PMID:33213122. |
through activation of the glp-1 receptor they not only have an important role stimulating insulin secretion after meals, but with their extrapancreatic actions, both peripheral and central, they also help reduce body weight by promoting satiety and delaying gastric emptying. |
2021-10-28 |
2023-08-13 |
Not clear |
| Yukiho Sasaoka, Taichi Takagi, Shunta Michiba, Yohei Yamamoto, Yuya Kumagai, Hideki Kishimur. Study on the Mechanism of the Blood-Glucose-Lowering Effect of Collagen Peptides from Sturgeon By-Products. Marine drugs. vol 19. issue 10. 2021-10-26. PMID:34677483. |
in subsequent oral and intravenous glucose administration tests, glucagon-like peptide-1 (glp-1) and insulin levels in the blood of mice were maintained at high levels. |
2021-10-26 |
2023-08-13 |
mouse |
| Yukiho Sasaoka, Taichi Takagi, Shunta Michiba, Yohei Yamamoto, Yuya Kumagai, Hideki Kishimur. Study on the Mechanism of the Blood-Glucose-Lowering Effect of Collagen Peptides from Sturgeon By-Products. Marine drugs. vol 19. issue 10. 2021-10-26. PMID:34677483. |
these results suggested the following three mechanisms: scps slow the rate of transportation of glucose from the stomach into the small intestine, resulting in delayed glucose absorption; scps suppress the absorption of glucose in the small intestine and excrete it from the body; scps inhibit dpp-iv in the blood and maintain a high glp-1 level in blood, which in turn stimulates insulin secretion. |
2021-10-26 |
2023-08-13 |
mouse |
| Rami Lee, Sun-Hye Choi, Han-Sung Cho, Hongik Hwang, Hyewhon Rhim, Hyoung-Chun Kim, Sung-Hee Hwang, Seung-Yeol Na. Effect of the Gintonin-Enriched Fraction on Glucagon-Like-Protein-1 Release. Molecules (Basel, Switzerland). vol 26. issue 20. 2021-10-26. PMID:34684879. |
the effect of the gintonin-enriched fraction (gef) on in vitro and in vivo glucagon-like protein-1 (glp-1) secretion, which is known to stimulate insulin secretion, via lpa receptor(s) remains unclear. |
2021-10-26 |
2023-08-13 |
mouse |
| Daria Ja'arah, Mazhar Salim Al Zoubi, Gamal Abdelhady, Firas Rabi, Murtaza M Tambuwal. Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia. Clinical medicine insights. Endocrinology and diabetes. vol 14. 2021-10-26. PMID:34690504. |
a relatively recent addition to the arsenal of antidiabetic drugs used for the treatment of type 2 diabetes mellitus (t2dm) has been the "incretin mimetics," a group of drugs that work on the glucagon-like peptide-1 (glp-1) receptor and enhance insulin secretion from the pancreatic β-cells in a glucose-dependent manner, more potently in hyperglycemic conditions, while suppressing glucagon secretion at the same time. |
2021-10-26 |
2023-08-13 |
human |
| Rithika Mary Koshy, Cornelius James Fernandez, Koshy Jaco. A Review of the Efficacy and Cardiovascular Safety of Amylin Analogues. Current drug safety. vol 16. issue 2. 2021-10-25. PMID:33153424. |
in this article, we will review the efficacy of pramlintide when given with insulin in improving hba1c, weight, and cognition with- /without glp-1 ras as well as its cardiovascular (cv) safety. |
2021-10-25 |
2023-08-13 |
Not clear |
| Ruth Hanssen, Alina Chloé Kretschmer, Lionel Rigoux, Kerstin Albus, Sharmili Edwin Thanarajah, Tamara Sitnikow, Corina Melzer, Oliver A Cornely, Jens C Brüning, Marc Tittgemeye. GLP-1 and hunger modulate incentive motivation depending on insulin sensitivity in humans. Molecular metabolism. vol 45. 2021-10-25. PMID:33453418. |
glp-1 and hunger modulate incentive motivation depending on insulin sensitivity in humans. |
2021-10-25 |
2023-08-13 |
Not clear |
| Ruth Hanssen, Alina Chloé Kretschmer, Lionel Rigoux, Kerstin Albus, Sharmili Edwin Thanarajah, Tamara Sitnikow, Corina Melzer, Oliver A Cornely, Jens C Brüning, Marc Tittgemeye. GLP-1 and hunger modulate incentive motivation depending on insulin sensitivity in humans. Molecular metabolism. vol 45. 2021-10-25. PMID:33453418. |
this type of reward circuity is particularly sensitive to the metabolic state signalled by peripheral mediators, such as insulin or glucagon-like peptide 1 (glp-1). |
2021-10-25 |
2023-08-13 |
Not clear |
| Asuka Uto, Kazutoshi Miyashita, Sho Endo, Masaaki Sato, Masaki Ryuzaki, Kenichiro Kinouchi, Masanori Mitsuishi, Shu Meguro, Hiroshi Ito. Transient Dexamethasone Loading Induces Prolonged Hyperglycemia in Male Mice With Histone Acetylation in Dpp-4 Promoter. Endocrinology. vol 162. issue 12. 2021-10-25. PMID:34480538. |
the blood glucose level in glucose tolerance tests, level of insulin and glucagon-like peptide 1 (glp-1), and the activity of dipeptidyl peptidase 4 (dpp-4) were examined during and after dexa loading in mice, with histone acetylation level of the promoter region. |
2021-10-25 |
2023-08-13 |
mouse |
| Amit Joharapurkar, Samadhan Kshirsagar, Vishal Patel, Maulik Patel, Hardikkumar Savsani, Mukul Jai. In vivo antidiabetic activity of nimesulide due to inhibition of amino acid transport. Basic & clinical pharmacology & toxicology. 2021-10-25. PMID:34634192. |
nimesulide treatment improved insulin sensitivity and glycemic control, increased glp-1, decreased liver lipids and improved fgf-21 in serum. |
2021-10-25 |
2023-08-13 |
mouse |
| Hwi Seung Kim, Chang Hee Jun. Oral Semaglutide, the First Ingestible Glucagon-Like Peptide-1 Receptor Agonist: Could It Be a Magic Bullet for Type 2 Diabetes? International journal of molecular sciences. vol 22. issue 18. 2021-10-22. PMID:34576096. |
glucagon-like peptide-1 (glp-1) is an incretin peptide hormone released from the lower digestive tract that stimulates insulin secretion, suppresses glucagon secretion, and decreases hunger. |
2021-10-22 |
2023-08-13 |
Not clear |
| Arpita Kalla Vyas, Lauren B Aerni-Flessner, Maria A Payne, Attila Kovacs, Patrick Y Jay, Paul W Hru. Saxagliptin Improves Glucose Tolerance but not Survival in a Murine Model of Dilated Cardiomyopathy. Cardiovascular endocrinology. vol 1. issue 4. 2021-10-21. PMID:23795310. |
glucagon-like peptide 1 (glp-1) agonists improve myocardial function and insulin sensitivity in the setting of chronic heart failure. |
2021-10-21 |
2023-08-12 |
mouse |
| Jose A Viscarra, Ruben Rodriguez, Jose Pablo Vazquez-Medina, Andrew Lee, Michael S Tift, Stephen K Tavoni, Daniel E Crocker, Rudy M Orti. Insulin and GLP-1 infusions demonstrate the onset of adipose-specific insulin resistance in a large fasting mammal: potential glucogenic role for GLP-1. Physiological reports. vol 1. issue 2. 2021-10-21. PMID:23997935. |
insulin and glp-1 infusions demonstrate the onset of adipose-specific insulin resistance in a large fasting mammal: potential glucogenic role for glp-1. |
2021-10-21 |
2023-08-12 |
Not clear |
| Jose A Viscarra, Ruben Rodriguez, Jose Pablo Vazquez-Medina, Andrew Lee, Michael S Tift, Stephen K Tavoni, Daniel E Crocker, Rudy M Orti. Insulin and GLP-1 infusions demonstrate the onset of adipose-specific insulin resistance in a large fasting mammal: potential glucogenic role for GLP-1. Physiological reports. vol 1. issue 2. 2021-10-21. PMID:23997935. |
to determine whether fasting results in insulin resistance or in pancreatic dysfunction, we infused early- and late-fasted seals (naturally adapted to prolonged fasting) with insulin (0.065 u/kg), and a separate group of late-fasted seals with low (10 pm/kg) or high (100 pm/kg) dosages of glucagon-like peptide-1 (glp-1) immediately following a glucose bolus (0.5g/kg), and measured the systemic and cellular responses. |
2021-10-21 |
2023-08-12 |
Not clear |
| Jose A Viscarra, Ruben Rodriguez, Jose Pablo Vazquez-Medina, Andrew Lee, Michael S Tift, Stephen K Tavoni, Daniel E Crocker, Rudy M Orti. Insulin and GLP-1 infusions demonstrate the onset of adipose-specific insulin resistance in a large fasting mammal: potential glucogenic role for GLP-1. Physiological reports. vol 1. issue 2. 2021-10-21. PMID:23997935. |
because glp-1 facilitates glucose-stimulated insulin secretion, these infusions provide a method to assess pancreatic insulin-secreting capacity. |
2021-10-21 |
2023-08-12 |
Not clear |
| Jose A Viscarra, Ruben Rodriguez, Jose Pablo Vazquez-Medina, Andrew Lee, Michael S Tift, Stephen K Tavoni, Daniel E Crocker, Rudy M Orti. Insulin and GLP-1 infusions demonstrate the onset of adipose-specific insulin resistance in a large fasting mammal: potential glucogenic role for GLP-1. Physiological reports. vol 1. issue 2. 2021-10-21. PMID:23997935. |
despite the dose-dependent increases in insulin and increased glucose clearance (high dose), both glp-1 dosages produced increases in plasma cortisol and glucagon, which may have contributed to the glucogenic role of glp-1. |
2021-10-21 |
2023-08-12 |
Not clear |
| Rosario Caltabiano, Daniele Condorelli, Salvatore Panza, Carla Boitani, Nicolò Musso, Davor Ježek, Lorenzo Memeo, Lorenzo Colarossi, Vittoria Rago, Valentina Mularoni, Saveria Spadola, Roberto Castiglione, Marta Santoro, Saveria Aquila, Rosario D'Agat. Glucagon-like peptide-1 receptor is expressed in human and rodent testis. Andrology. vol 8. issue 6. 2021-10-18. PMID:33460247. |
the incretin hormone glucagon-like peptide-l (glp-1) is an important regulator of post-prandial insulin secretion, acting through a g protein-coupled cell surface receptor (glp-1r). |
2021-10-18 |
2023-08-13 |
human |